Interaction Between Cannabinoid System and Toll-Like Receptors Controls Inflammation

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2016 Sep 7

PMID 27597805

Citations 40

Authors

Kathleen L McCoy

Affiliations

Soon will be listed here.

Abstract

Since the discovery of the endocannabinoid system consisting of cannabinoid receptors, endogenous ligands, and biosynthetic and metabolizing enzymes, interest has been renewed in investigating the promise of cannabinoids as therapeutic agents. Abundant evidence indicates that cannabinoids modulate immune responses. An inflammatory response is triggered when innate immune cells receive a danger signal provided by pathogen- or damage-associated molecular patterns engaging pattern-recognition receptors. Toll-like receptor family members are prominent pattern-recognition receptors expressed on innate immune cells. Cannabinoids suppress Toll-like receptor-mediated inflammatory responses. However, the relationship between the endocannabinoid system and innate immune system may not be one-sided. Innate immune cells express cannabinoid receptors and produce endogenous cannabinoids. Hence, innate immune cells may play a role in regulating endocannabinoid homeostasis, and, in turn, the endocannabinoid system modulates local inflammatory responses. Studies designed to probe the interaction between the innate immune system and the endocannabinoid system may identify new potential molecular targets in developing therapeutic strategies for chronic inflammatory diseases. This review discusses the endocannabinoid system and Toll-like receptor family and evaluates the interaction between them.

Citing Articles

Endocannabinoid and hematological responses to pre- and post-therapeutic exercises in liver transplant patients.

AlShahrani A, Al-Khlaiwi T, Meo S, Siddiqui I, Alghanem B, Almourfi F Am J Clin Exp Immunol. 2025; 13(6):259-271.

PMID: 39839347 PMC: 11744344. DOI: 10.62347/FNLX9490.

Examining the moderating role of cannabis use on the relationship between alcohol consumption and inflammation in individuals with alcohol use disorder.

Grodin E, McManus K, Ray L Addict Biol. 2024; 29(8):e13431.

PMID: 39091190 PMC: 11294675. DOI: 10.1111/adb.13431.

Neuroactive Steroids, Toll-like Receptors, and Neuroimmune Regulation: Insights into Their Impact on Neuropsychiatric Disorders.

Balan I, Boero G, Chery S, McFarland M, Lopez A, Morrow A Life (Basel). 2024; 14(5).

PMID: 38792602 PMC: 11122352. DOI: 10.3390/life14050582.

Beyond prediction: unveiling the prognostic power of μ-opioid and cannabinoid receptors, alongside immune mediators, in assessing the severity of SARS-CoV-2 infection.

Tavakoli-Yaraki M, Abbasi A, Pishkenari F, Baranipour S, Jahangirifard A, Mirtajani S BMC Infect Dis. 2024; 24(1):398.

PMID: 38609845 PMC: 11015610. DOI: 10.1186/s12879-024-09280-6.

Perturbation of 3D nuclear architecture, epigenomic aging and dysregulation, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 2-Metabolome, immunome, synaptome.

Reece A, Hulse G Front Psychiatry. 2023; 14:1182536.

PMID: 37854446 PMC: 10579598. DOI: 10.3389/fpsyt.2023.1182536.

References

Kagan J, Su T, Horng T, Chow A, Akira S, Medzhitov R . TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol. 2008; 9(4):361-8. PMC: 4112825. DOI: 10.1038/ni1569. View

Di Marzo V . 2-Arachidonoyl-glycerol as an "endocannabinoid": limelight for a formerly neglected metabolite. Biochemistry (Mosc). 1998; 63(1):13-21. View

Buckley N . The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol. 2007; 153(2):309-18. PMC: 2219525. DOI: 10.1038/sj.bjp.0707527. View

Ohashi K, Burkart V, Flohe S, Kolb H . Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000; 164(2):558-61. DOI: 10.4049/jimmunol.164.2.558. View

Maresz K, Carrier E, Ponomarev E, Hillard C, Dittel B . Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005; 95(2):437-45. DOI: 10.1111/j.1471-4159.2005.03380.x. View

Downer E, Clifford E, Gran B, Nel H, Fallon P, Moynagh P . Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J Biol Chem. 2011; 286(12):10316-28. PMC: 3060486. DOI: 10.1074/jbc.M110.188599. View

Cravatt B, Demarest K, Patricelli M, Bracey M, Giang D, Martin B . Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001; 98(16):9371-6. PMC: 55427. DOI: 10.1073/pnas.161191698. View

Varga K, Wagner J, Bridgen D, Kunos G . Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 1998; 12(11):1035-44. DOI: 10.1096/fasebj.12.11.1035. View

Liu J, Batkai S, Pacher P, Harvey-White J, Wagner J, Cravatt B . Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem. 2003; 278(45):45034-9. DOI: 10.1074/jbc.M306062200. View

10.

Correa F, Mestre L, Docagne F, Guaza C . Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol. 2005; 145(4):441-8. PMC: 1576166. DOI: 10.1038/sj.bjp.0706215. View

11.

Malfitano A, Basu S, Maresz K, Bifulco M, Dittel B . What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol. 2014; 26(5):369-79. PMC: 4567276. DOI: 10.1016/j.smim.2014.04.002. View

12.

Stella N . Cannabinoid signaling in glial cells. Glia. 2004; 48(4):267-77. DOI: 10.1002/glia.20084. View

13.

Roth M, Baldwin G, Tashkin D . Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids. 2002; 121(1-2):229-39. DOI: 10.1016/s0009-3084(02)00159-7. View

14.

Di Marzo V, De Petrocellis L, Bisogno T . The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol. 2006; (168):147-85. DOI: 10.1007/3-540-26573-2_5. View

15.

Molina-Holgado F, Pinteaux E, Moore J, Molina-Holgado E, Guaza C, Gibson R . Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci. 2003; 23(16):6470-4. PMC: 6740626. View

16.

Tashkin D, Baldwin G, Sarafian T, Dubinett S, Roth M . Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol. 2002; 42(S1):71S-81S. DOI: 10.1002/j.1552-4604.2002.tb06006.x. View

17.

Jeon Y, Yang K, Pulaski J, Kaminski N . Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol. 1996; 50(2):334-41. View

18.

Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P . Endocannabinoids and immune regulation. Pharmacol Res. 2009; 60(2):85-92. PMC: 3044336. DOI: 10.1016/j.phrs.2009.03.019. View

19.

Svensson M, Chen P, Hammarfjord O . Dendritic Cell Regulation by Cannabinoid-Based Drugs. Pharmaceuticals (Basel). 2016; 3(8):2733-2750. PMC: 4033947. DOI: 10.3390/ph3082733. View

20.

Syed Y, McKeage K, Scott L . Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs. 2014; 74(5):563-78. DOI: 10.1007/s40265-014-0197-5. View